Signalling in osteoclasts and the role of Fos/AP1 proteins

E F Wagner, K Matsuo


The analysis of genetically modified mice and cells has provided important new insights into the biological functions of the dimeric transcription factor complex AP1. The key components of AP1, the Fos and Jun proteins, have essential roles in bone development, because these proteins influence the activity of all bone cells, including chondrocytes, osteoblasts, and osteoclasts. New AP1 functions and their downstream effectors were recently discovered using conditional mutagenesis in the mouse as well as by genome-wide analysis of AP1 inducible genes, in particular in the osteoclast lineage.

The signal transduction pathways operating in osteoclastogenesis have been extensively studied and how extracellular stimuli lead to the activation of key transcriptional programmes is beginning to be understood. The events downstream of macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL) signalling are well described. Positive and negative regulatory loops are in place, which involve the activation of NF-κB and Jun N-terminal kinase (JNK), eventually leading to the expression of AP1/Fos, an essential regulator of osteoclast differentiation.

AP1 consists of a large variety of dimers composed of members of the Fos proteins—Fos, FosB, Fra1, and Fra2; the three Jun proteins—Jun, JunB, and JunD; and ATF proteins (for review see Karsenty and Wagner1 and Jochum et al2). AP1 acts like a biosensor in cells and is often considered as a stress responsive transcription factor complex. Being at the receiving end of several signal transduction cascades, AP1 activity converts extracellular signals from, for example, growth factor receptors, through mitogen activated protein kinase (MAPK) into changes in gene expression via expression of AP1 responsive target genes. The activity of AP1 is regulated at different levels—transcriptional and post-transcriptional; it is also modulated by interactions with other transcriptional regulators. AP1 activity is implicated in a wide range of biological processes, including cell proliferation, differentiation, apoptosis, and oncogenesis.1,2 Here we will give a brief summary of the current knowledge and understanding of AP1 functions in bone development and will focus on the role of AP1 in signalling in osteoclasts. These data were largely obtained from an analysis of genetically modified mice and cells, in which specific AP1 genes were ectopically expressed, constitutively or conditionally inactivated, mutated, or replaced by each other.

AP1 PROTEINS IN BONE DEVELOPMENT

AP1 proteins have important roles as key regulators of bone development.3 The generation of transgenic mice overexpressing Fos proteins has underlined the function of AP1 in osteoblasts, the bone forming cells, which are affected by the activity of different Fos proteins. Fos overexpression induces osteosarcomas, a bone tumour characterised by the transformation of cells of the osteoblastic lineage.4 On the other hand, mice overexpressing either a Fos target gene, Fra1, which is also known as Fos-like antigen 1, Fosl1, or the short isoform of FosB, AFosB, develop osteosclerosis, which is characterised by increased bone mass due to enhanced osteoblast differentiation.4 None of the AP1 members seem to be essential in determining the osteoblastic lineage. The function of AP1 in the development of the skeleton is not restricted to the mesenchymal lineage. Fos is also essential for osteoclast differentiation, as demonstrated by the complete absence of osteoclasts in mice lacking Fos (see below).

To better understand how Fos and Fra1 control osteoblast and osteoclast differentiation, conditional alleles of Fos and Fra1 were generated. The embryonic lethality caused by inactivation of Fra1 in the placenta was rescued with a conditional allele using MORE-cre mice, which results in specific deletion of Fra1 in the embryo proper. The mutant mice are viable but develop osteopenia, a mild form of osteoporosis due to decreased osteoblast differentiation (Eferl R and Wagner E, personal communication). The phenotype of Fra1 deficient osteoblasts correlates with the osteoblastic phenotype seen upon Fra1 overexpression. These data indicate that the expression level of Fos proteins can regulate the activity of the osteoblastic lineage. Interestingly, gene replacement of Fos by Fra1 showed functional equivalence of these two proteins.7 Finally, inactivation of Fra2 gives rise to pups, which also exhibit severe osteoporosis and die at birth, probably due to heart failure (Eferl R and Wagner E, unpublished data).

Jun proteins are essential for mouse development, because absence of these proteins causes embryonic death.7 Conditional mutagenesis using the Cre-lox system provided important new insights into the functions of Jun and JunB in bone development. Chondrocyte-specific deletion of Jun leads to a failure of intravertebral disc formation, and mutant mice develop severe scoliosis.8 On the other hand, conditional deletion of JunB with the embryo-specific MORE-Cre line rescues the lethality, although the mutant mice develop severe osteoporosis characterised by defects in both osteoblasts and osteoclasts (Kenner L and Wagner E, unpublished data).

SIGNALLING IN OSTEOCLASTS

The signal transduction pathways operating in osteoclastogenesis have been extensively studied. We are beginning to understand how extracellular stimuli through intracellular signalling lead to the expression and activation of key transcription factors.7 Osteoclast differentiation is controlled by two essential cytokines, M-CSF and RANKL (fig 1 and for review see Karsenty and Wagner1). The key function of M-CSF was demonstrated by the analysis of a naturally occurring op/op mutation in mice, which carries an inactivating point mutation in the gene encoding M-CSF.910 op/op mice are osteopetrotic owing to a lack of macrophage and osteoclast differentiation and thus of bone resorption. The defect can be rescued by injection of exogenous M-CSF, as well as by crossing the op/op mice with mice overexpressing the anti-apoptotic protein Bcl2. These results show that M-CSF acts as a growth and survival factor for the common monocytes precursor shared between macrophages and osteoclasts.

Abbreviations: AP1, activating protein; IFN, interferon; JNK, Jun N-terminal kinase; MAPK, mitogen activated protein kinase; MAPKK, mitogen activated protein kinase kinase; M-CSF, macrophage colony-stimulating factor; RANKL, receptor activator of NF-κB ligand; TNF, tumour necrosis factor; TRAF, TNF receptor associated factor.
The second cytokine, RANKL, was first characterised as a ligand for the osteoclast inhibitory factor osteoprotegerin, a circulating decoy receptor belonging to the tumour necrosis factor (TNFα) receptor family. Gene inactivation studies demonstrated that RANKL, through binding to its receptor RANK, is essential for osteoclastogenesis, but does not affect macrophage differentiation. Thus, RANKL is the key molecule controlling the switch between macrophages and osteoclasts. Gene inactivation experiments have also made it possible to identify the transcription factors specifically controlling the osteoclast switch. Mice lacking Fos and mice lacking two members of the NF-κB family, p50 and p52, display very similar phenotypes. They are both osteopetrotic owing to a block in osteoclast differentiation, while macrophages accumulate in the bone marrow.

The exact signalling pathway connecting RANKL to NF-κB is still unclear. The requirement of the TNF receptor associated factor 6 (TRAF6) for NF-κB activation is well established. Two different mouse lines lacking TRAF6 were generated, which both are osteopetrotic, but display significant differences. In one line, osteoclast differentiation is impaired, whereas in the second line osteoclasts do differentiate, but are inactive. In both lines, the interleukin 1 induced activation of NF-κB is completely blocked. The role of TRAF6 in NF-κB activation was further confirmed by studying the mechanism by which type II interferon (IFNβ) inhibits osteoclast differentiation. IFNβ increased the ubiquitin mediated degradation of TRAF6, leading to a block in RANKL induced NF-κB.

OSTEOCLASTS AND AP1 ACTIVITY

The generation of multiple knockout mice affecting AP1 signalling pathways has permitted a more complete dissection of AP1 regulation in osteoclasts. RANKL is a known inducer of JNKs, which phosphorylate the Jun component of AP1. IFNγ was also shown to block RANKL induced JNK activation. Using JNK1 or JNK2 deficient monocytes, we have shown that inactivation of JNK1, but not of JNK2, leads to decreased osteoclast differentiation in vitro. Similar defects were seen when monocytes were isolated from mice expressing a phosphorylation deficient Jun (JunAA). Moreover, JNK1 protects monocytes against RANKL induced apoptosis independently of Jun phosphorylation.

The early embryonic lethality observed in mice lacking Jun or JunB long prevented the study of Jun functions in osteoclasts. Recently, monocytes lacking Jun or JunB were successfully generated using Cre mediated conditional deletion. A decrease in osteoclast differentiation was observed in vitro with both Jun or JunB deficient monocytes, while the absence of JunD had no effect. These data indicate that Jun and JunB are both probably partners of Fos in osteoclast differentiation.

Although the essential function of Fos for osteoclast differentiation has long been established, we are only just beginning to understand how Fos is regulated during osteoclast differentiation and, more importantly, what the key downstream targets are (see below). Type I interferon (IFNβ) inhibits osteoclast differentiation by post-transcriptionally blocking Fos expression. Surprisingly, Fos itself directly regulates IFNβ synthesis in osteoclasts, thereby establishing an autoinhibitory loop (fig 1). Moreover, post-transcriptional modifications of Fos in response to M-CSF stimulation were identified. Fos was shown to be phosphorylated in its C-terminal domain on serine 362 and 374 by ERK (also known as MAPK1), and the ERK dependent kinase RSK-2. Phosphorylation of these two sites is believed to stabilise Fos. Pretreatment of osteoclast progenitors with IFNβ inhibits M-CSF induced ERK activation. Finally, the inhibition of the upstream ERK-activating kinase MEK1 (also known as mitogen activated protein kinase kinase 1, MAPKK1) was proposed as the mechanism by which IFNβ blocks osteoclast differentiation (David J-P and Wagner E, unpublished data).

In addition to IFNβ, the Fos related protein Fra1 has been described as a Fos target in osteoclasts. Although Fra1 is not essential for osteoclast differentiation, decreased osteoclast differentiation was seen in mice lacking Fra1, confirming that Fra1 can potentiate the efficiency of osteoclastogenesis.
RANKL DEPENDENT GENE EXPRESSION

To explore comprehensively the signalling pathways downstream of RANKL, a genome-wide screening of RANKL inducible genes was performed. Microarray analyses of wild-type precursors treated with RANKL showed that the expression of several transcription factors, in particular of NFATc1, is strongly up regulated by RANKL. NFATc1 encoding a transcription factor that interacts with API, was identified as a TRAF6 and Fos target gene in osteoclasts. Northern blot analysis showed that NFATc1 expression is abolished in Fos−/−precursors. A key function of NFATc1 in osteoclastogenesis was further demonstrated by showing that no osteoclasts could be generated from embryonic stem cells lacking NFATc1. In addition, ectopic expression of NFATc1 in osteoclast progenitors induced osteoclast differentiation in the absence of RANKL. These data suggest that NFATc1 is a key downstream target and partner of c-Fos for osteoclast differentiation.

Fos DEPENDENT GENE EXPRESSION

Genome-wide analyses of Fos target genes using both cDNA and oligonucleotide based microarrays was also performed to discover new downstream effectors of Fos signalling. A comparison between wild-type and Fos−/− precursors in osteoclastogenic cultures disclosed preferential expression of a number of interferon inducible genes in wild-type cultures (our unpublished results). This led to the identification of the IFNβ mediated negative feedback regulation of osteoclastogenesis. This analysis again showed the lack of NFATc1 expression in Fos−/− precursors. Importantly, the introduction of an activated form of NFATc into Fos−/− precursor cells rescued osteoclast formation as well as bone resorption and restored transcription of osteoclast marker genes (Matsuo et al., manuscript in preparation), indicating that the lack of transcriptional activation of NFATc1 is the cause of the differentiation block in the osteoclast precursors lacking Fos. It appears that NFATc1 acting as a direct target gene of Fos and RANKL signalling is a new key regulator for terminal differentiation of osteoclasts.

ACKNOWLEDGEMENTS

The IMP is supported by Boehringer-Ingelheim and EFW thanks PD for help in preparing the manuscript.

-----------------------

Authors’ affiliations

E F Wagner, IMP, Research Institute of Molecular Pathology, Dr. Bohr-Gasse 7, A-1030 Vienna, Austria
K Matsuo, Keio University School of Medicine, Tokyo, Japan

Correspondence to: Dr E F Wagner; wagner@imp.univie.ac.at

REFERENCES


www.annrheumdis.com
Signalling in osteoclasts and the role of Fos/AP1 proteins

E F Wagner and K Matsuo

doi: 10.1136/ard.62.suppl_2.ii83

Updated information and services can be found at:
[http://ard.bmj.com/content/62/suppl_2/ii83](http://ard.bmj.com/content/62/suppl_2/ii83)

These include:

**References**
This article cites 24 articles, 8 of which you can access for free at:
[http://ard.bmj.com/content/62/suppl_2/ii83#BIBL](http://ard.bmj.com/content/62/suppl_2/ii83#BIBL)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)